Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing selonabant, a product candidate intended to address acute cannabinoid intoxication. The company is still pre-commercial and has not generated revenue since inception, so its value proposition is centered on advancing its lead program through development and, if approved, building a path to commercialization. Anebulo does not currently have a sales organization, which means it would need to build commercial capabilities internally or partner with third parties to market and distribute any approved product. Its business model is therefore highly dependent on clinical progress, regulatory approval, and the ability to secure commercialization partners or create a sales infrastructure.

— Anebulo Pharmaceuticals, Inc.
%
Lead drug candidate100% Selonabant is the company's primary investigational asset and the focus of its development efforts.
Clinical development services0% Internal and outsourced activities to advance the drug through trials, regulatory work, and manufacturing support.
Future commercialization rights0% Potential sales, marketing, and distribution of approved pharmaceutical products through internal or partnered channels.

Anebulo does not currently sell pharmaceutical products, so it has no commercial customer base today...

  • No current commercial customersprimary

    The company has no marketed products and therefore no revenue-generating customer base today.

  • Healthcare providersprimary

    Hospitals, emergency departments, and clinicians would use or prescribe selonabant if approved for acute cannabinoid intoxication.

  • Third-party payorsprimary

    Insurers and government payors would determine coverage and reimbursement, which are essential for adoption.

  • Commercial partnerssecondary

    Potential partners may market, sell, and distribute approved products on Anebulo's behalf.

  • Clinical research organizations and trial sitessecondary

    These organizations support development activities by running studies and handling clinical operations.

Anebulo is headquartered in the United States and its development and future commercialization plans are centered on...

  • •Headquartered in the United States
  • •Primary commercial focus is the U.S. market
  • •U.S. reimbursement and managed care policies are key to adoption
  • •May pursue partners in selected U.S. and non-U.S. markets
  • •No country revenue disclosure because the company has no revenue

Anebulo's near-term strategy is to advance selonabant through development and position the asset for regulatory...

01
Advance selonabant toward approvalshort-term

The company has no revenue and its value depends on successful development of its lead asset.

02
Build or source commercialization capabilitymedium-term

Without sales and marketing infrastructure, the company cannot launch a product on its own.

03
Secure market access and reimbursementmedium-term

Coverage and reimbursement will determine whether an approved product can achieve meaningful uptake.

Anebulo faces substantial development-stage risk because it has not generated revenue and may never become profitable...

critical

Clinical and regulatory failure of selonabant

As a single lead-asset development company, failure of the core program would materially impair future value.

Scope
Lead product candidate
Materiality
high
high

No revenue and ongoing losses

The company has not generated revenue since inception and expects future losses, so it depends on external financing and successful development.

Scope
Entire business model
Materiality
high
high

Lack of commercialization infrastructure

The company has no sales organization and no direct experience marketing pharmaceutical products.

Scope
Future product launch
Materiality
high
medium

Pricing and reimbursement pressure

Managed care, coverage restrictions, and cost containment policies can limit access and reduce realized pricing.

Scope
U.S. market access
Materiality
medium
medium

Healthcare compliance and fraud-and-abuse laws

Commercial relationships with HCPs, payors, CROs, and customers are subject to extensive regulation.

Scope
Commercial and medical affairs activities
Materiality
medium
Accrued research and development expenses
Can materially affect operating expenses and liabilities
Emerging growth company reporting
Affects transparency and comparability
Equity and warrant-related accounting
Can affect shareholders' equity and non-cash charges

LeonaBio, Inc.

LONA · Biological Products, (No Diagnostic Substances)

CNBX Pharmaceuticals Inc.

CNBX · Pharmaceutical Preparations

Dianthus Therapeutics, Inc. /DE/

DNTH · Pharmaceutical Preparations

ALUMIS INC.

ALMS · Pharmaceutical Preparations

Annexon, Inc.

ANNX · Pharmaceutical Preparations

Apogee Therapeutics, Inc.

APGE · Biological Products, (No Diagnostic Substances)

: 11/08/2026